A5102012389- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Bladder and Urothelial Cancer Treatments
- Virus-based gene therapy research
- Urinary and Genital Oncology Studies
- Immunotherapy and Immune Responses
- Urological Disorders and Treatments
- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- Glioma Diagnosis and Treatment
- Nanowire Synthesis and Applications
- Immune Response and Inflammation
- Cancer Research and Treatments
- Viral Infectious Diseases and Gene Expression in Insects
- RNA Interference and Gene Delivery
- Advancements in Semiconductor Devices and Circuit Design
- Ferroptosis and cancer prognosis
- Nanoparticle-Based Drug Delivery
- Renal and related cancers
- Renal cell carcinoma treatment
- Lymphoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Immune cells in cancer
Sichuan University
2019-2025
Qingdao University
2010-2025
Affiliated Hospital of Qingdao University
2021-2025
State Key Laboratory of Biotherapy
2019-2024
West China Hospital of Sichuan University
2024
Qingdao Municipal Hospital
2013-2015
Shandong University
2013
Chinese Academy of Sciences
1997-2003
Center for Excellence in Molecular Cell Science
1997-2002
Shanghai Institutes for Biological Sciences
2000-2002
Glioblastoma (GBM) remains one of the most malignant primary tumors in adults, with a 5-year survival rate less than 10% because lacking effective treatment. Here, we aimed to explore whether B7-H3 could serve as novel therapeutic target for GBM chimeric antigen receptor (CAR) T cell therapy. In this study, CAR targeting was constructed and transduced into cells by lentivirus. Antitumor effects B7-H3-specific CAR-T were assessed lines both vitro vivo. Our results indicated that positively...
Glioblastoma (GBM) is the most aggressive primary malignant brain cancer and urgently requires effective treatments. Chimeric antigen receptor T (CAR-T) cell therapy offers a potential treatment method, but it often hindered by poor infiltration of CAR-T cells in tumors highly immunosuppressive tumor microenvironment (TME). Here, we armed an oncolytic adenovirus (oAds) with chemokine CXCL11 to increase reprogram TME, thus improving its therapeutic efficacy. In both immunodeficient...
Purpose: Given that heterogeneous expression and variants of antigens on solid tumors are responsible for relapse after chimeric antigen receptor (CAR)-T cell therapy, we hypothesized combinatorial targeting two tumor-associated would lessen this problem enhance the antitumor activity T cells. Methods:The co-expression level CD70 B7-H3 was analyzed in multiple tumor tissue samples.Further, putative were identified The Cancer Genome Atlas Gene Expression Profiling Interactive Analysis...
Recently, B7-H3 was frequently reported to be overexpressed in various cancer types and has been suggested a promising target for immunotherapy. In the present study, we analyzed mRNA expression of The Cancer Genome Atlas (TCGA) database validated its across multiple types. We then generated novel B7-H3-targeted chimeric antigen receptor (CAR) tested antitumor activity both
Abstract Background The outbreak and pandemic of coronavirus SARS-CoV-2 caused significant threaten to global public health economic consequences. It is extremely urgent that people must take actions develop safe effective preventions therapeutics. Nanobodies, which are derived from single‑chain camelid antibodies, had shown antiviral properties in various challenge viruses. In this study, multivalent nanobodies with high affinity blocking spike interaction ACE2 protein were developed....
Abstract Objective We conducted a first‐in‐human study to evaluate the bioactivity and safety of B7‐H3‐targeted chimeric antigen receptor (CAR) autologous T cells for treating recurrent anaplastic meningioma. Methods Tumor tissues from patient with meningioma were evaluated B7‐H3 expression. CAR‐T delivered into intracranial tumor resection cavity using an Ommaya device at maximum dose 1.5 × 10 7 cells. Magnetic resonance imaging (MRI) screening multiple serum indexes regularly monitored....
The therapeutic use of bispecific T-cell engaging (BiTE) antibodies has shown great potential for treating malignancies. BiTE can simultaneously engage CD3ε on T cells and tumor antigen cancer cells, thus exerting an effective antitumor effect. Nevertheless, challenges in production, manufacturing, short serum half-life have dampened some the promise impeded pace BiTE-based therapeutics to combat diseases. Nowadays, vitro-transcribed mRNA achieved programmed which is more flexible...
Abstract Multiple myeloma (MM) remains a challenging hematologic malignancy despite advancements in chimeric antigen receptor T-cell (CAR-T) therapy. Current targets of CAR-T cells used MM immunotherapy have limitations, with subset patients experiencing loss resulting relapse. Therefore, novel for enhancing cell therapy remain needed. Fc receptor-like 5 (FCRL5) is protein marker considerably upregulated expression and has emerged as promising target therapeutic interventions, offering an...
Recent studies have indicated that combining oncolytic viruses with CAR-T cells in therapy has shown superior anti-tumor effects, representing a promising approach. Nonetheless, the localized delivery method of intratumoral injection poses challenges for treating metastatic tumors or distal are difficult to reach. To address this obstacle, we employed HSV-1-infected cells, which systemically HSV into solid tumors. The biological function remained intact after loading them period three days....
Triple-negative breast cancer (TNBC) comprises lethal malignancies with limited treatment options. Chimeric antigen receptor T (CAR-T) cell therapy is an effective immunotherapeutic strategy that has demonstrated unprecedented efficacy in the of hematological but shown success management some solid tumors. Many malignant tumors are related to increased expression intercellular adhesion molecule-1 (ICAM1), providing a rationale for ICAM1-specific immunotherapies cancer. Here, we validated...
Abstract Background Chimeric antigen receptor (CAR) T cells and immune checkpoint blockades (ICBs) have made remarkable breakthroughs in cancer treatment, but the efficacy is still limited for solid tumors due to tumor heterogeneity microenvironment. The restrained treatment prompted us seek new potential therapeutic methods. Methods In this study, we conducted a small molecule compound library screen human BC cell line identify whether certain drugs contribute CAR killing. Signaling...
Abstract Background BCMA-directed autologous chimeric antigen receptor T (CAR-T) cells have shown excellent clinical efficacy in relapsed or refractory multiple myeloma (RRMM), however, the current preparation process for CAR-T is complicated and costly. Moreover, upregulation of CD47 expression has been observed myeloma, anti-CD47 antibodies remarkable results trials. Therefore, we focus on development BCMA/CD47-directed universal (UCAR-T) to improve these limitations. Methods In this...
The aim of the present study was to evaluate association between levels lipids and B-type natriuretic peptide (BNP) in systemic lupus erythematosus (SLE) patients with heart failure (HF). A total 46 active SLE 40 healthy, age-matched control subjects were studied. BNP measured by an immunofluorescence assay fresh plasma. Total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL-C), low-density cholesterol, apolipoprotein (Apo) B, ApoA-I lipoprotein(a) assessed. Compared...
Extranodal nasal natural killer (NK)/T cell lymphoma (ENKTCL) is a rare but highly aggressive subtype of non-Hodgkin (NHL). Nevertheless, despite extensive research, the estimated 5-year overall survival affected patients remains low. Therefore, new treatment strategies are needed urgently. Recent advances in immunotherapy have potential to broaden applications chimeric antigen receptor-modified T (CAR-T) cells and bispecific T-cell engaging (BiTE) antibody. Here, we screened panel...
Antibody-drug conjugates (ADCs) offer a promising approach, combining monoclonal antibodies with chemotherapeutic drugs to target cancer cells effectively while minimizing toxicity.
Oxidative stress has been linked to the progression of mutations and cancer. Increased glutathione (GSH) contents have observed in a number different human cancer tissues. GSH is synthesized de novo two-step process catalyzed by glutamate cysteine ligase (GCL). The present study aimed investigate whether GCL was associated with renal cell carcinoma (RCC). protein expression levels subunits (catalytic subunit, GCLc; modulatory GCLm) activity were examined tissue. A total 46 patients...
Abstract Glioblastoma (GBM) is a highly malignant intracranial tumor with limited treatment options. Bispecific T‐cell engagers (BiTEs) are being explored for GBM treatment, but their success hindered by inadequate T cell infiltration and activation due to the acidic immunosuppressive microenvironment. Photothermal immunotherapy lyses tumors activates immune responses, complementing BiTEs. This study innovatively employs donor engineering strategy develop hemicyanine dyes (Hcys) that emit...
<p>Supplementary Figure 4. LC-MS analysis and average DAR value of antibody-drug conjugates. A, SLC3A2/PD-L1 BsADC. LC-MS, liquid chromatography-MS. The BsADC was 0.82. B, SLC3A2 ADC. 1.63. C, PD-L1 ADC 0.93.</p>